Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanford-Burnham Teams With Pfizer

by Rick Mullin
August 19, 2013 | A version of this story appeared in Volume 91, Issue 33

Sanford-Burnham Medical Research Institute and Pfizer will jointly identify new therapeutic targets for preventing and treating complications of obesity and diabetes. The partners will use screening tools and systems biology techniques developed by Sanford-Burnham to discover means of reducing insulin resistance in both diseases. Investigational compounds from Pfizer will be screened at Sanford-Burnham’s Conrad Prebys Center for Chemical Genomics in La Jolla, Calif. “Pfizer’s collaboration with Sanford-Burnham to use their cutting-edge screen designs is an example of our strategy to work with academic innovators to discover novel therapeutics for prevention and treatment of diabetes,” says Tim Rolph, head of cardiovascular and metabolic diseases research at Pfizer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.